Journal
NEUROLOGY
Volume 77, Issue 11, Pages 1048-1054Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1212/WNL.0b013e31822e560e
Keywords
-
Categories
Funding
- Boehringer Ingelheim
- Teva Pharmaceutical Industries Ltd.
- Desitin Pharmaceuticals
- GmbH
- GE Healthcare
- Michael J. Fox Foundation for Parkinson's Research
- American Parkinson's Disease Association
- Stifterverband fur die Deutsche Wissenschaft
Ask authors/readers for more resources
Objective: To investigate the frequency, phenomenology, and associated risk factors of REM sleep behavior disorder (RBD) in Parkinson disease (PD). Methods: An unselected cohort of sleep-disturbed patients with PD (n = 457) was investigated with video-supported polysomnography. We determined the frequency of RBD and analyzed the influence of age, clinical disease features, disease duration, cognitive and physical impairment, medication, comorbidity, and sleep architecture. Results: The overall frequency of RBD was 46%. According to our cohort and modified definition, there was no preferred PD subtype for RBD (p = 0.142). There was no gender preference (p = 0.770). RBD was associated with older age (p = 0.000). Adjusted for age and gender, patients with PD and RBD had longer disease duration (p = 0.024), higher Hoehn & Yahr stages (p = 0.002), more falls (p = 0.018), more fluctuations (p = 0.005), more psychiatric comorbidity (p = 0.026), and a higher dose of levodopa (p = 0.002). The presence of RBD was related to slightly increased sleep efficiency (p = 0.007), a higher amount of REM sleep (p = 0.000), and more periodic leg movements during sleep (p = 0.019). Conclusion: RBD is a frequent and clinically relevant nocturnal disturbance for all stages of PD. It increases with age and disease duration and may contribute to the nocturnal problems of patients with PD and their bed partners. Neurology (R) 2011; 77: 1048-1054
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available